Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on the Isolation of Gene Polymorphism in Schizophrenia in People of the Kazakh Ethnic Group

NCT05090644 | Completed

• 1 other identifier: 1203
• Study Type: observational
• Target: 700
• Locations: 1 country
• Sites: 1

Brief Summary

This is a GWAS study that aims to identify possible candidate genes associate to schizophrenia by exploring single nucleotide polymorphism (SNP) in a group of schizophrenia, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associated with schizophrenia

Conditions

Schizophrenia

Keywords

GWAS

Outcome Measures

Primary Outcomes (1)

• number of SNPs associated with schizophrenia

  Using GWAS to identify candidate genes associate with schizophrenia

  1 year

Study Arms (2)

Experimental group:

Patients with schizophrenia

Genetic: DNA analysis

Control group

Patients without schizophrenia

Genetic: DNA analysis

Interventions

DNA analysis GENETIC

GWAS

Control group; Experimental group:

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Kazakh population

You may qualify if:

• persons of Kazakh nationality having this ethnicity in the 3rd generation
• age from 18 to 65 years old;
• the dispensary in a psychiatric institution at the place of residence with a diagnosis of "Paranoid schizophrenia";
• the duration of the disease is at least 1 year (from the moment of taking under dispensary supervision):
• absence of severe and chronic somatic diseases;
• absence of severe and chronic neurological diseases;
• absence of comorbid drug addiction pathology;
• signed informed consent to conduct this study

You may not qualify if:

• persons of non-Kazakh nationality and Kazakh nationality, not confirmed until the 3rd generation
• age less than 18 years old and over 65 years old;
• those who are on dispensary registration in a psychiatric institution at the place of residence with a diagnosis not related to ICD-10 under the heading F20.0 "Paranoid schizophrenia";
• having a disease duration of less than 1 year (from the moment of taking under dispensary supervision):
• having severe and chronic somatic diseases;
• having severe and chronic neurological diseases;
• having comorbid narcological pathology;
• not signed informed consent to conduct this study

Sponsors & Collaborators

• Asfendiyarov Kazakh National Medical University: lead

Study Sites (1)

Republican Scientific and Practical Center for Mental Health

Almaty, 050000, Kazakhstan

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Study Officials

• Kuanysh Altynbekov, PhD

  Republican Scientific and Practical Center for Mental Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of the Laboratory of Experimental Medicine

Study Record Dates

• First Submitted: September 25, 2021
• First Posted: October 25, 2021
• Study Start: March 30, 2022
• Primary Completion: January 20, 2023
• Study Completion: January 20, 2023
• Last Updated: March 14, 2023

Record last verified: 2023-03

Locations

KA (1)